Katelin A Mirkin1, Erin K Greenleaf1, Christopher S Hollenbeak1,2, Joyce Wong3. 1. Division of Surgical Oncology, Department of Surgery, College of Medicine, The Pennsylvania State University, 500 University Drive, MC H070, Hershey, PA, 17033, USA. 2. Department of Public Health Sciences, College of Medicine, The Pennsylvania State University, Hershey, PA, USA. 3. Division of Surgical Oncology, Department of Surgery, College of Medicine, The Pennsylvania State University, 500 University Drive, MC H070, Hershey, PA, 17033, USA. joyce.wong02@gmail.com.
Abstract
BACKGROUND: Pancreatic surgery encompasses complex operations with significant potential morbidity. Greater experience in minimally invasive surgery (MIS) has allowed resections to be performed laparoscopically and robotically. This study evaluates the impact of surgical approach in resected pancreatic cancer. METHODS: The National Cancer Data Base (2010-2012) was reviewed for patients with stages 1-3 resected pancreatic carcinoma. Open approaches were compared to MIS. A sub-analysis was then performed comparing robotic and laparoscopic approaches. RESULTS: Of the 9047 patients evaluated, surgical approach was open in 7511 (83%), laparoscopic in 992 (11%), and robotic in 131 (1%). The laparoscopic and robotic conversion rate to open was 28% (n = 387) and 17% (n = 26), respectively. Compared to open, MIS was associated with more distal resections (13.5, 24.3%, respectively, p < 0.0001), shorter hospital length of stay (LOS) (11.3, 9.5 days, respectively, p < 0.0001), more margin-negative resections (75, 79%, p = 0.038), and quicker time to initiation of chemotherapy (TTC) (59.1, 56.3 days, respectively, p = 0.0316). There was no difference in number of lymph nodes obtained based on surgical approach (p = 0.5385). When stratified by type of resection (head, distal, or total), MIS offered significantly shorter LOS in all types. Multivariate analysis demonstrated no survival benefit for any MIS approach relative to open (all, p > 0.05). When adjusted for patient, disease, and treatment characteristics, TTC was not an independent prognostic factor (HR 1.09, p = 0.084). CONCLUSION: MIS appears to offer comparable surgical oncologic benefit with improved LOS and shorter TTC. This effect, however, was not associated with improved survival.
BACKGROUND: Pancreatic surgery encompasses complex operations with significant potential morbidity. Greater experience in minimally invasive surgery (MIS) has allowed resections to be performed laparoscopically and robotically. This study evaluates the impact of surgical approach in resected pancreatic cancer. METHODS: The National Cancer Data Base (2010-2012) was reviewed for patients with stages 1-3 resected pancreatic carcinoma. Open approaches were compared to MIS. A sub-analysis was then performed comparing robotic and laparoscopic approaches. RESULTS: Of the 9047 patients evaluated, surgical approach was open in 7511 (83%), laparoscopic in 992 (11%), and robotic in 131 (1%). The laparoscopic and robotic conversion rate to open was 28% (n = 387) and 17% (n = 26), respectively. Compared to open, MIS was associated with more distal resections (13.5, 24.3%, respectively, p < 0.0001), shorter hospital length of stay (LOS) (11.3, 9.5 days, respectively, p < 0.0001), more margin-negative resections (75, 79%, p = 0.038), and quicker time to initiation of chemotherapy (TTC) (59.1, 56.3 days, respectively, p = 0.0316). There was no difference in number of lymph nodes obtained based on surgical approach (p = 0.5385). When stratified by type of resection (head, distal, or total), MIS offered significantly shorter LOS in all types. Multivariate analysis demonstrated no survival benefit for any MIS approach relative to open (all, p > 0.05). When adjusted for patient, disease, and treatment characteristics, TTC was not an independent prognostic factor (HR 1.09, p = 0.084). CONCLUSION: MIS appears to offer comparable surgical oncologic benefit with improved LOS and shorter TTC. This effect, however, was not associated with improved survival.
Entities:
Keywords:
MIS; Minimally invasive surgery; NCDB; Pancreatic cancer; Time to adjuvant therapy
Authors: Paul J Speicher; Daniel P Nussbaum; Rebekah R White; Sabino Zani; Paul J Mosca; Dan G Blazer; Bryan M Clary; Theodore N Pappas; Douglas S Tyler; Alexander Perez Journal: Ann Surg Oncol Date: 2014-06-13 Impact factor: 5.344
Authors: Kristopher P Croome; Michael B Farnell; Florencia G Que; K Marie Reid-Lombardo; Mark J Truty; David M Nagorney; Michael L Kendrick Journal: Ann Surg Date: 2014-10 Impact factor: 12.969
Authors: Deniece Riviere; Kurinchi Selvan Gurusamy; David A Kooby; Charles M Vollmer; Marc G H Besselink; Brian R Davidson; Cornelis J H M van Laarhoven Journal: Cochrane Database Syst Rev Date: 2016-04-04
Authors: Camille L Stewart; Cheryl Meguid; Brandon Chapman; Richard Schulick; Barish H Edil Journal: Ann Surg Oncol Date: 2016-08-10 Impact factor: 5.344
Authors: Daniel R Principe; Patrick W Underwood; Murray Korc; Jose G Trevino; Hidayatullah G Munshi; Ajay Rana Journal: Front Oncol Date: 2021-07-15 Impact factor: 6.244